Spectrum Joins Growing Race for Rituximab Biosimilar
By Tom Wall
Thursday, January 6, 2011
If imitation is the highest form of praise, it appears that a growing list of companies think very highly of rituximab and its multi-billion-dollar world market.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.